BUSINESS
Clean Science and Technology IPO: Clean and richly valued
CSTL is among the few companies globally focussed on developing eco-friendly and cost-competitive technologies using in-house catalytic processes
BUSINESS
Demand for medical gloves gives this stock a distinct edge
Apcotex plans to spend Rs 100-110 crore over FY22 and early FY23 if environmental permission for the XNBR latex plant at Valia comes through
BUSINESS
Solara Active: Build-up of CRAMS pipeline to help rerate
Solara is looking at utilising cash flows to build a project pipeline for CRAMS, capitalising on inorganic opportunities
BUSINESS
Bodal Chemicals: Benzene benefit to show up from FY24
Business diversification seems to be an attempt to reduce volatility in profitability from the dyes industry and gain exposure to more stable chemicals
BUSINESS
Reliance’s foray into green energy will boost India’s renewable energy ambitions and geopolitical standing
RIL AGM 2021: India’s energy sector is on the cusp of a solar powered revolution and Reliance is set to play a leading role in it
BUSINESS
India Pesticides IPO: What does this have in store for investors?
India Pesticides, with one of the best return ratios in the industry, has swiftly ramped up its capacity in recent years indicating good order book and strong linkage with formulators
TRENDS
US Fed meet ratchets up inflation fears and tapering talk
While the Fed Chair sounded dovish, he dropped hints of a significant change in the macroeconomic context in the last six months which may warrant tapering or rate hike earlier than expected, puncturing the equity rally
BUSINESS
IPO radar | Is KIMS a dark horse in the making?
The growth strategy at KIMS is based on volume play driven by hinterland opportunities
BUSINESS
Lupin: Somerset warning implies regulatory environment may no longer offer relief
In its Indian business, Lupin is expected to remain steady due to a better mix and outperformance in chronic therapies
BUSINESS
Monsoon Watch | The perils of an extended monsoon
If the monsoon gets extended, it can impact the kharif crop, thereby potentially putting pressure on food inflation
BUSINESS
US inflation spike: A signal for repeat of taper tantrum?
While the decision on policy rate hikes or the withdrawal of quantitative easing is quite some time away, any talk of such a plan can still create jitters in financial markets
BUSINESS
NOCIL: The end of capex cycle ups free cash flow prospects
Faster execution of the ‘China plus’ opportunity will be a trigger for rerating for NOCIL
BUSINESS
HEG goes big on capacity, pins hopes on earnings recovery
HEG stock’s performance is contingent on the earnings cycle as realisations pick up
BUSINESS
Sharda Cropchem: Domestic COVID disruptions no dampener for this value play
Localised COVID restrictions are unlikley to have any impact on Sharda Cropchem. Most of its sales as well as raw material sourcing are outside India where economic activities have almost normalised
BUSINESS
Rossari Biotech: Expanding growth opportunities, but has the stock run its course in the short term?
We see Rossari Biotech as a worthy growth stock with exceptional earnings growth rates, but post 60 per cent jump in stock price from our note in October 2020, investors can take profit off the table
BUSINESS
IPCA Labs: Strong margins to sustain even post-COVID opportunities
In spite of the extraordinary sales of Hydroxychloroquine in FY21, IPCA Labs expects a 9-10 per cent growth in topline for FY22
BUSINESS
Aurobindo Pharma: US reopening, traction for COVID vaccine near-term growth opportunity
The most positive development for the last fiscal year has been a sharp reduction in leverage which positions Aurobindo Pharma for capex commitments in the API, vaccine and biosimilars space
BUSINESS
Divi’s Labs: Vertical integration keeps it ahead of peers
The macro context is fragile, more so because of the second COVID wave. As a result, liquidity will continue to chase businesses such as Divi's Labs that are cash rich and have positive cash flows
BUSINESS
Sun Pharma: Traction in speciality likely to sustain
Sun Pharma's key specialty products, particularly Ilumya (plaque psoriasis) and Cequa (dry eye disease), held up well
BUSINESS
Cadila: All in for COVID while keeping a tab on complex pharma
Cadila's stock has been primed by a series of potential rollouts to meet the COVID challenge
BUSINESS
Herd Immunity Tracker: About 18% of Indian adults have taken booster doses
China continues to struggle with the target of “Societal zero”
BUSINESS
Balaji Amines: Execution lifts margin profile
Balaji Amines has upgraded its EBITDA margin guidance from the 20-22 per cent range to 24-26 per cent for FY22
BUSINESS
Rain Industries: A play on global economy getting back to normalcy
Rain Industries' capex run rate dropped in Q1 CY21 versus the average quarterly spend in CY20. This helps in better free cash flow and facilitates debt reduction
BUSINESS
Dhanuka Agritech: Still offers margin of safety
The Centre’s efforts to bring down import of oilseeds and pulses are key positives for Dhanuka. Additionally, the commencement of Dahej plant would enable backward integration as well as open export opportunities
